JPRN-jRCTs051220065
Recruiting
Phase 2
Phase II study of chemotherapy plus nivolumab followed by conversion surgery for Stage IV gastric cancer with a single non-curable factor(Chemo+ICI followed by CS for Stage IV gastric cancer) - Chemo+ICI followed by CS for Stage IV gastric cancer
Kurokawa Yukinori0 sites70 target enrollmentJuly 22, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kurokawa Yukinori
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adenocarcinoma has been diagnosed by histopathological examination.
- •2\) HER2 is negative.
- •3\) Untreated cStage IV gastric cancer or esophagogastric junction cancer (esophageal infiltration length within 3 cm).
- •4\) Have one of the following nonhealing factors (not eligible if two or more)
- •Distant lymph node metastasis (not suitable for No 16a2 / b1 only)
- •Peritoneal dissemination (P3 is not suitable only for P1 / P2 in the 12th edition of the Gastric Cancer Handling Regulations)
- •Liver metastasis (up to 5 metastases, regardless ofsize, but limited to those that can be resected) Lung metastasis (limited to one side, all of which are judged to be resectable) Bone metastasis (limited to those that can be irradiated in one field when irradiating) Ovarian metastasis (both sides are acceptable) Adrenal metastasis (both sides are acceptable)
- •5\) The age is between 20 and 85\.
- •6\) PS (ECOG) is 0 or 1\.
- •7\) Prognosis of 3 months or more is expected.
Exclusion Criteria
- •1\) Have active double cancer (simultaneous double cancer / multiple cancers and metachronous double cancers / multiple cancers with a disease\-free period of 5 years or less, but if topical treatment is curable or expected to survive for 3 years or more Registration is possible).
- •2\) Previous treatment history of antiPD1 antibody, antiPDL1 antibody, antiPDL2 antibody, antiCD137 antibody or antiCTLA4 antibody or other antibody therapy or drug therapy for T cell control.
- •3\) Has a history of gastrectomy (however, a history ofbypass surgery for oral ingestion is acceptable).
- •4\) Have a history of active bacterial or fungal infections or tuberculosis.
- •5\) Has a history of serious heart disease, heart failure, myocardial infarction or unstable angina within 6
- •months from the date of registration.
- •6\) have diabetes with poor control.
- •7\) be pregnant, breastfeeding or pregnant.
- •8\) Has a history of autoimmune disease (collagen disease).
- •9\) Has a history of severe interstitial pneumonia.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.2024-515064-31-00Medical University Of Gdansk84
Not yet recruiting
Phase 2
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Moneo trial2024-516777-77-00Vall D Hebron Institute Of Oncology30
Active, not recruiting
Phase 1
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003334-25-DEniversity of Cologne90
Active, not recruiting
Phase 2
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaAggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaDiffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedIndolent Non-Hodgkin LymphomaMediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaTransformed Non-Hodgkin LymphomaNCT03749018David Bond, MD30
Active, not recruiting
Phase 1
A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.Previously untreated metastatic clear cell renal cell carcinoma.MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-001476-33-GBniversity of Leeds189